Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.91
+0.51000.72%
Post-market: 70.910.00000.00%16:15 EDT
Volume:372.12K
Turnover:26.28M
Market Cap:3.94B
PE:6.39
High:71.08
Open:70.33
Low:70.13
Close:70.40
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:0.78
T/O Rate:0.67%
Dividend:0.81
Dividend Rate:1.14%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.41
PE(LYR):23.18

Loading ...

OverviewCompanyNewsFilings

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26

Merck & Co - Two Additional Phase 3 Trials Underway for Ifinatamab Deruxtecan in Crpc and Escc

THOMSON REUTERS
·
Sep 26

UnitedHealth Announces R$ 0.115248942 Dividend Per Unit for 3Q 2026

Reuters
·
Sep 26

Exchange-Traded Funds Rise US Equities Advance After Midday

MT Newswires Live
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

Dow Jones
·
Sep 25

Exchange-Traded Funds, Equity Futures up Pre-Bell Friday as Treasury Yields Rise, Oil Prices Fall

MT Newswires Live
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25
More